November 9-11, 2020 | Virtual Conference

Speakers

Scott Lassman, J.D.

Principal
Lassman Law+Policy

Scott M. Lassman is the Principal at Lassman Law+Policy, a boutique law firm located in Washington, D.C. that focuses on solving its clients’ most complicated FDA-related problems.  Scott provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them.  His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters.

Scott also has extensive experience with the FDA Citizen Petition process and, when necessary, litigating FDA disputes in federal court. He has successfully protected his clients’ interests through litigation in a wide variety of matters, including Hatch-Waxman exclusivity, 180-day exclusivity, pediatric exclusivity, user fees, and approval requirements.  Scott is author of the Exclusivity Rules blog, which focuses on the written and unwritten rules governing FDA’s exclusivity decisions.  The blog is available at: www.lassmanfdalaw.com/blog/.

Before starting Lassman Law+Policy, Scott was the Chair of the FDA Practice Group at a leading, international law firm, a partner at a well-regarded FDA boutique, and the head FDA regulatory attorney at a major pharmaceutical trade association.  Scott graduated from Yale University (B.A.), the University of Texas at Austin (M.A.), and the University of Virginia School of Law (J.D.).

Scott enjoys working in a boutique environment and founded Lassman Law+Policy so that he could devote more time to his clients. When not practicing law, Scott is an avid amateur photographer, tennis player, and chef.

Get Started + Register

Whether you are an AAM member, general attendee, speaker or exhibitor, you can be part of the premier scientific and regulatory conference for the U.S. generics and biosimilars industry.

Get Started + Register

Whether you are an AAM member, general attendee, speaker or exhibitor, you can be part of the premier scientific and regulatory conference for the U.S. generics and biosimilars industry.

Skip to content